IBUS-SAS was not significantly different in patients with clinically active disease (HBI ≥ 5) versus clinically inactive disease (66.2 ± 29.2 vs 52.3 ± 20.8, p = 0.06), and was not statistically different between patients with fecal calprotectin ≥ 150 μg/g versus < 150 μg/g (62.0 ± 25.4 vs 43.0 ± 24.0, p = 0.06) and between patients with CRP > 3.0 mg/L versus ≤ 3.0 mg/L (63.5 ± 26.3 vs 60.2 ± 30.2, p = 0.72). Here, CRP is linked to SATB2 associated disorder.